Albireo Pharma Ownership

ALBO Stock  USD 44.95  0.40  0.90%   
Some institutional investors establish a significant position in stocks such as Albireo Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Albireo Pharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Please continue to Trending Equities.
  
Albireo Pharma Debt to Equity Ratio is quite stable at the moment as compared to the past year. The company's current value of Debt to Equity Ratio is estimated at 0.07. Price to Sales Ratio is expected to rise to 10.19 this year, although the value of PPandE Turnover will most likely fall to 67.56.
Albireo Pharma retains a total of 20.74 Million outstanding shares. The majority of Albireo Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Albireo Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Albireo Pharma. Please pay attention to any change in the institutional holdings of Albireo Pharma as this could imply that something significant has changed or about to change at the company. Also note that nearly four hundred fourteen thousand eight hundred ninety-eight invesors are currently shorting Albireo Pharma expressing very little confidence in its future performance.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Albireo Stock Ownership Analysis

About 98.0% of the company shares are held by institutions such as insurance companies. The book value of Albireo Pharma was presently reported as 4.84. The company recorded a loss per share of 1.7. Albireo Pharma last dividend was issued on the 4th of November 2016. The entity had 1:30 split on the 4th of November 2016. Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. Albireo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 130 people. For more info on Albireo Pharma please contact Ronald Cooper at 857 254 5555 or go to https://www.albireopharma.com.

Albireo Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Albireo Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Albireo Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Albireo Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
22nd of August 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
15th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition. Termination of a Material Definitive Agreement. Entry into a Material Definitive Agreement
View
29th of July 2022
Termination of a Material Definitive Agreement
View

Albireo Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Albireo Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Albireo Pharma backward and forwards among themselves. Albireo Pharma's institutional investor refers to the entity that pools money to purchase Albireo Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares5.7 K123.5 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K95 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K97 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K146 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K114 K
Wolverine Trading LlcCall Options17.3 K307 K
Wipfli Financial Advisors LlcCommon Shares56411 K
Winton Group LtdCommon Shares13.2 K337 K
Note, although Albireo Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Albireo Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Albireo Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Albireo Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Albireo Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Albireo Pharma Investors Sentiment

The influence of Albireo Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Albireo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Albireo Pharma's public news can be used to forecast risks associated with investment in Albireo. The trend in average sentiment can be used to explain how an investor holding Albireo can time the market purely based on public headlines and social activities around Albireo Pharma. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Albireo Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Albireo Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Albireo Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Albireo Pharma.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albireo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albireo Pharma's short interest history, or implied volatility extrapolated from Albireo Pharma options trading.

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-0.78CVSCVS Health Corp Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Valuation
Check real value of public entities based on technical and fundamental data
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
915.3 M
Quarterly Revenue Growth
1.683
Return On Assets
(0.25) 
Return On Equity
(0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.